<DOC>
	<DOCNO>NCT01667978</DOCNO>
	<brief_summary>The purpose study learn woman take atazanavir ritonavir low level birth control medication call norethindrone . Norethindrone ( also call mini pill ) FDA ( Food Drug Administration ) approve progestin-only birth control pill use prevent pregnancy . Norethindrone standard medication use woman take progestin pill prevent pregnancy . There birth control pill contain different medication . The investigator want learn HIV medication ( atazanavir ritonavir ) make blood level birth control pill high low . If level norethindrone low may work prevent pregnancy . The investigator also hope learn change vaginal fluid cervical fluid woman take birth control pill .</brief_summary>
	<brief_title>The Effect Protease Inhibitors Pharmacokinetics Oral Norethindrone Contraception</brief_title>
	<detailed_description>BACKGROUND/RATIONALE : It recognize dearth clinically apply , population base , empiric data guide contraceptive recommendation HIV + woman ARVs . ( 1 ) Protease inhibitor ( PI ) non nucleoside reverse transcriptase inhibitor ( NNRTI ) induce micro enzyme system CYP 3a4 , turn alters bio-availability pharmacokinetics concurrently administer medication . ( 2 ) Empiric trial small sample , often 10-20 HIV negative subject , demonstrate concurrent administration combine oral contraceptive ( COC ) PI NNRTI associate decreased plasma ethinyl estradiol ( EE ) level . These pharmacokinetic finding raise concern decrease bio-availability EE may result decreased contraceptive efficacy , possible increase unintended pregnancy . Some COC study demonstrate change serum level norethindrone ( NET ) ARVs . ( 3-16 ) However , publish trial focus oral NET oral progestin-only pill ( POP ) guide management HIV+ woman . ( 17 ) OBJECTIVES : Primary objective study : To detect Â±40 % difference AUC serum NET HIV+ woman take ATV/RTV compare AUC NET HIV+ woman take ARV regimen demonstrate interaction NET past . Primary endpoint : Natural log-transformed NET PK parameter AUC 0 72 hour follow oral administration , multiple discrete serum data point subject ATV/RTV . This compare natural log-transformed NET PK AUC 0 72 hour follow oral administration , multiple discrete serum data point control HIV+ woman take ARV regimen demonstrate interaction NET past . The secondary objective study : To evaluate effect ATV/RTV PK exposure endpoints parameter NET ( natural log transformation ) . The sample control group mention compare . Endpoints include : minimum plasma concentration ( Cmin ) , maximum plasma concentration ( Cmax ) , time Cmax ( Tmax ) , half-life ( T1/2 ) . SAMPLE SIZE : Recruitment 16 participant arm , goal attain 32 evaluable HIV-1-seropositive female subject total . POPULATION/STUDY ARMS : HIV-1-infected female subject 18-44 year age METHODOLOGY/INTERVENTIONS/FOLLOW-UP : A two-arm , open-label , prospective , steady state trial characterize pharmacokinetics ( PK ) oral norethindrone ( NET ) progestin contraceptive pill ( POP ) HIV+ woman receive atazanavir ritonavir therapy ( ATV/RTV ) . The investigator identify control group HIV+ woman take ARV regimens significantly altered oral NET level prior trial . Subjects enrol trial approximately 4 week A 28 day continuous packet NET 0.35 mg provide enrolled volunteer 21 day continuous administration . Women participate study demonstrate mean continue ARV regimens duration study , ARV therapy provide study . On day 22 subject admit serial pharmacokinetic ( PK ) specimens collection follow final study dose NET . Subjects enrol one 2 arm base current ARV regimen . Study group : Women stable ARV/RTV ( 300/100mg daily ) additional ARV regimens significantly altered oral NET level prior trial . ( n=12 ) . Control group : Stable current ARV , protease inhibitor ( PI ) , ARV regimens significantly altered oral NET level previous research . OUTCOMES : Intensive PK sample NET perform intervention control arm 21 day NET administration . To determine side effect profile NET self-administered daily questionnaire 3-4 week study enrollment period STATISTICS : Area concentration-time curve ( AUC ) , peak plasma concentration , low plasma concentration NET HIV+ woman receive PI therapy determine compare similar value HIV positive control subject take PI therapy . Statistical consultation obtain USC Keck School Medicine Department Bio statistic Laboratory Applied Pharmacokinetics</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<criteria>Ages : 1844 year Gender : female Accepts : healthy volunteer HIV1 infect woman Acceptable medication include : medication , NRTI combination , entry inhibitor , integrase inhibitor , CCR5 agonists . NRTI combination may include limited : zidovudine ( ZDV ) , lamivudine ( 3TC ) , emtricitabine ( FTC ) , didanosine ( ddl ) , stavudine ( d4T ) , abacavir ( ABC ) , tenofovir disoproxil fumarate ( TDF ) . NNRTI : etravirine , rilpivirine . Exclusion criterion : History bilateral oophorectomy , ovarian dysfunction regular period . CD4+ cell count &lt; 200 cells/mm3 No current uncontrolled thyroid , liver , renal disease BMI &lt; 40 kg/m^2 Current pregnancy , breastfeed pregnancy within 30 day enrollment . Depomedroxyprogesterone acetate injection ( DMPA ) within 180 day prior study entry . Other hormonal therapy ( e.g . oral contraceptive agent , Provera , vaginal ring , contraceptive patch , monthly contraceptive injection , hormone replacement therapy , anabolic therapy , include nandrolone decanoate megestrol acetate ) within 21 day prior study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>contraception</keyword>
	<keyword>mini pill</keyword>
	<keyword>norethindrone</keyword>
	<keyword>atazanavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>norvir</keyword>
	<keyword>reyataz</keyword>
	<keyword>pregnancy prevent</keyword>
	<keyword>birth control</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>antiviral</keyword>
	<keyword>antiretroviral</keyword>
</DOC>